The effect of CYP3A41G allele on the pharmacokinetics of atorvastatin in Chinese han patients with coronary heart disease

Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2014, Pages 462-467

  He, Bao Xia ^a,b   Shi, Lei ^b   Qiu, Jian ^b   Zeng, Xiao Hui ^b   Zhao, Shu Jin ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

coronary heart disease; CYP3A4; genetic polymorphism; pharmacokinetics

Indexed keywords

2VHYDROXYATORVASTATIN; ATORVASTATIN; CYTOCHROME P450 3A4; UNCLASSIFIED DRUG; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ASIAN; BLOOD; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PHARMACOKINETICS;

CORONARY HEART DISEASE; CYP3A4; GENETIC POLYMORPHISM; PHARMACOKINETICS;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY DISEASE; CYTOCHROME P-450 CYP3A; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES;

EID: 84898619731     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.229     Document Type: Article

References (22)

1. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376: 1916-1922.
2. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000; 28: 1369-1378.
3. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG,. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica. 2008; 38: 1240-1251.
4. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M,. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007; 82: 726-733. (Pubitemid 350114817)
5. Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat. 2004; 23: 100.
6. Du J, Yu L, Wang L, et al. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin Chim Acta. 2007; 383: 172-174. (Pubitemid 47016454)
7. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH,. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf. 2010; 19: 75-81.
8. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W,. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011; 11: 274-286.
9. Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005; 5: 352-358.
10. Gao Y, Zhang LR, Fu Q,. CYP3A41G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol. 2008; 64: 877-882.
11. Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004; 14: 523-525. (Pubitemid 39100004)
12. He BX, Shi L, Qiu J, et al. Quantitative determination of atorvastatin and ortho-hydroxy atorvastatin in human plasma by liquid chromatography tandem mass spectrometry and pharmacokinetic evaluation. Methods Find Exp Clin Pharmacol. 2010; 32: 481-487.
13. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR,. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS ONE. 2012; 7: e44064.
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006; 26: 1895-1900. (Pubitemid 44305347)
15. He BX, Shi L, Qiu J, et al. A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol. 2011; 108: 208-213.
16. Qiu XY, Jiao Z, Zhang M, et al. Association of MDR1, CYP3A418B, and CYP3A53 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2008; 64: 1069-1084.
17. Zuo XC, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013; 23: 251-261.
18. Wang YY, Zhang M, Lu FM, Jiao Z, Qiu XY,. CYP3A4 genetic polymorphisms predict cyclosporine-related clinical events in Chinese renal transplant recipients. Chin Med J (Engl). 2012; 125: 4233-4238.
19. Miura M, Satoh S, Kagaya H, et al. Impact of the CYP3A41G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics. 2011; 12: 977-984.
20. Zhang W, Chang YZ, Kan QC, et al. CYP3A41G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol. 2010; 66: 61-66.
21. Yuan R, Zhang X, Deng Q, Wu Y, Xiang G,., Impact of CYP3A41G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clin Chim Acta. 2011; 412: 755-760.
22. Dong ZL, Li H, Chen QX, et al. Effect of CYP3A41G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population. J Clin Pharm Ther. 2012; 37: 153-156.